In the United States, it is reported that one in four adults suffer from brain injuries. Magnetic targeting to enable stem cell therapies to treat brain diseases has a wide scope in the market. The magnetic targeting would aim stem cells at desired location of the brain to treat the defected part of the brain. The stem cell therapies overcome the loss of neurotic cells in the brain, hence, magnetic targeting to enable induction of stem cells in the desired location of the brain to treat injuries is so far the best technology proposed by Magneto Biologics Inc. There is no other prominent business in the market utilizing the magnetic targeting technology to treat brain diseases such as neurodegenerative disease and other brain injuries. The magnetic targeting has the potential to treat Alzheimer, Parkinson disease, and traumatic brain injury. The duration of the license agreement is proposed to be of 10 years. In this period, Magneto Biologics Inc. would focus on expanding the business by implementing concentrated market strategies. The Licensed Magneto Biologics Inc. would aim at health market segments, offering the technology to hospitals and other medical concerned departments.
Other relevant market segments targeted would be medical facility centers, medical universities, and industrial market. The segmentation would help the Magneto Biologics to differentiate the technology from other similar technologies such as intraventricular injection available in the market. To the best of our knowledge no other company is working on the current technology. The market size is expanding radically because of the awareness of the technology in the relevant market segments. Large number of businesses are willing to invest and acquire the technology because of the projected growth. In Europe, it is estimated that 35% of all disease load is associated with brain disorders. In America, 5.4 million people are suffering from Alzheimer disease and other brain disorders. It is estimated by 2050, 115.4 million people will suffer from Alzheimer disease worldwide (Mc Govern Institute, 2014).
The projected growth of the market interested in magnetic targeting to enable stem cells to treat brain injuries by the year 2016 would be around 40%. The coming months in 2016 would be highly productive for the Magneto Biologics Inc. The sales are predicted to increase roughly by 20% as the product has wide acceptance in the market. Hence, the magnetic biologics has a lot of potentials to take over conventional ways of treating brain disorders.
Reference
Mc Govern Institute. (2014). Brain Disorders: By the Numbers. Retrieved from mcgovern.mit.edu: https://mcgovern.mit.edu/brain-disorders/by-the-numbers
